To include your compound in the COVID-19 Resource Center, submit it here.

AML’s growing options

A side-by-side look at new AML therapies

For acute myelogenous leukemia patients, 2017 marked the end of a more than 40 year drought in which chemotherapy was the only treatment option. In the last three years, eight new AML therapies have come to market spanning newly diagnosed and relapsed or refractory settings, and most target molecularly-defined patient subgroups.

Three of the newly approved agents target FLT3-mutated AML, and

Read the full 619 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE